期刊
CURRENT OPINION IN GASTROENTEROLOGY
卷 28, 期 4, 页码 321-326出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOG.0b013e328354be1e
关键词
molecular reclassification; Montreal classification; Paris classification; predictors disabling disease
资金
- Concerted Research Action [GOA/11/015]
Purpose of review Inflammatory bowel diseases (IBDs) are disorders of multifactorial cause that present as a multitude of phenotypes, clinical behaviours and severity. Crohn's disease and ulcerative colitis are considered as the two extremes of what is believed to be a spectrum of chronic gut inflammation and this separation is still the first classification used when confronted with an IBD patient. An accurate classification within IBD has several benefits, with respect to patient counselling, assessing risk for disease progression, and particularly with respect to choosing the most appropriate therapy for an individual patient. Basic scientists on the other hand prefer classifications that would allow to better understand the pathophysiology of the different manifestations of Crohn's disease and ulcerative colitis. Recent findings Attempts to reclassify IBD based on recent genetic, serologic or immunologic findings have been made. Most, however, have not been translated to daily practice and need confirmation first. Summary Clinicians should apply a systematic approach to their patients by using existing phenotypic classifications such as Montreal or Paris. They should further recognize clinical and endoscopic features of bad outcome such as perianal disease, deep ulcers on colonoscopy and extensive small bowel involvement.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据